Spirit Semiconductor Expanding Theale Headquarters and Opening Second Office in Leeds, UK
24.2.2021 12:10:00 EET | Business Wire | Press release
Spirit Semiconductor, an innovator in high-performance radio frequency solutions, today announced it will be moving to a new headquarters in Theale, U.K. and will be opening a new satellite office in Leeds, U.K. to tap into the strong radio frequency (RF) monolithic microwave integrated circuit (MMIC) and filter engineering talent in Northern England. The expansion comes on the heels of swift customer adoption and deployment of Spirit Semiconductor’s technology for 5G massive multiple-input and multiple-output (mMIMO) and small cell base stations.
Since the company’s inception in 2020, it has experienced rapid growth, developing a core team of 15 people in less than one year. Located in one of the U.K.’s technology hotbeds, the new office is five times larger than current Spirit headquarters, boasting 9,000 square feet of office space. The new Leeds office will support the company’s plans to expand its product portfolio and enter into other high growth markets.
“When Spirit Semiconductor was founded last year, we were solely focused on creating cutting edge radio frequency products for 5G mMIMO. Currently, our products are being evaluated by customers but the feedback we have received so far has been hugely positive and really provides us with the encouragement we need to branch out into other markets,” said Mark Moffat, managing director of Spirit Semiconductor. “At this rate, we are targeting 65% growth in 2021. This is only the beginning for our company, and I could not be more excited to see what the next year brings by way of innovation and expansion.”
“Massive MIMO architectures change the fundamental building blocks of the RF chain dramatically,” commented Joe Madden, chief analyst at Mobile Experts. “We are experiencing very rapid market growth for some RF components as the base station design adapts to 32T and 64T variations of massive MIMO, with tight performance requirements for RFICs to support a wide range of applications.”
Spirit Semiconductor is looking for the semiconductor industry’s top talent. The company is currently hiring for several positions: principal filter design engineer, principal MMIC design engineer, senior MMIC design engineer and senior analog IC design engineer. For additional information, contact Luke Ord at IC Resources, luke.ord@ic-resources.com, +44 118 907 3070.
“IC Resources is excited to be helping Spirit Semiconductor to identify the right talent to fuel its impressive growth,” commented Kathy Campling, client services director at IC Resources. “Spirit’s strong business plan, exciting product roadmap and generous benefits package are an attractive proposition to potential employees.”
About Spirit Semiconductor Ltd.
Spirit Semiconductor Ltd. is a United Kingdom based company, founded by experts in the radio frequency (RF) semiconductor industry. We are focused on developing high-performance RF products to support the rapid roll out of 5G massive MIMO (mMIMO), small cell base stations and other markets requiring high performance solutions. At Spirit Semiconductor our approach is intelligent innovation, fast implementation and strong team collaboration. We are an aggressive, fast-moving group that is focused on developing compelling products that meet our customers’ needs and timescales, while maintaining a strong team ethic and collaborative spirit. We believe in developing a balanced team that has all levels of experience and fostering an environment where everyone has the opportunity to learn and grow. To learn more, visit www.spiritsemiconductor.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005291/en/
Contact information
Olivia Metcalfe
Townsend Team
olivia@townsendteam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom